Ceftazidime Market estimated to be valued US$ XX Mn in 2021 and poised to grow at significant CAGR over 2022-2028 due to their wide spread usage in the treatment of intra-abdominal, skin and soft tissue, as well as obstetric and gynecological infections and increasing prevalence of various infections are the major factors that are driving the growth of the ceftazidime market. Moreover, implementation of government initiatives, technological advancements and rise in research and developmental activities and product innovations fuels the growth of the market. Additionally, robust development of the healthcare sector and pharmaceutical industry and expanding patient base across the globe to boost the growth of the Ceftazidime market. Also, rising concerns among the patient is propelling the manufacturers to conduct researches with regards to the antibiotics. Global ceftazidime market is surging owing to launch of innovative products in different markets to expand the portfolio and strengthen their position in the market. For instance, in March 2017, Pfizer Inc. announced that Zavicefta, a novel combination antibiotic for the treatment of patients with certain confirmed or suspected Gram-negative bacterial infections requiring hospitalization, is now available in the U.K. and Germany. For instance, Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for marketing the injections containing 1 Gm/Vial Ceftazidime, which is used for treating various kinds of infections.